Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

601 A

Next Previous
X
Search
Drug Profile

601 A

Alternative Names: 601; 601-A; 601A-AMD; 601A-DME; 601A-pmCNV; 601A-RVO; Anti-VEGF monoclonal antibody - Sunshine Guojian Pharmaceutical

Latest Information Update: 27 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3SBio
  • Developer 3SBio; Sunshine Guojian Pharmaceutical
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic macular oedema
  • Phase II Choroidal neovascularisation
  • Phase I Age-related macular degeneration; Wet age-related macular degeneration

Most Recent Events

  • 27 Dec 2022 Phase-III clinical trials in Diabetic macular oedema in China (Intravitreous) (NCT05520177)
  • 31 Aug 2022 601 A is still in phase-I development for Wet age-related macular degeneration (Treatment-experienced) in China (Intravitreous, Injection)
  • 29 Aug 2022 Sunshine Guojian Pharmaceutical plans a phase III trial for Diabetic macular oedema in China, in September 2022 (Intravitreous, Injection) (NCT05520177)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top